161 related articles for article (PubMed ID: 23048077)
41. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
42. Cellular and molecular effects of the mTOR inhibitor everolimus.
Saran U; Foti M; Dufour JF
Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
[TBL] [Abstract][Full Text] [Related]
43. Everolimus in diffuse large B-cell lymphomas.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
[TBL] [Abstract][Full Text] [Related]
44. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Hoang B; Frost P; Shi Y; Belanger E; Benavides A; Pezeshkpour G; Cappia S; Guglielmelli T; Gera J; Lichtenstein A
Blood; 2010 Nov; 116(22):4560-8. PubMed ID: 20686120
[TBL] [Abstract][Full Text] [Related]
45. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
Simioni C; Cani A; Martelli AM; Zauli G; Tabellini G; McCubrey J; Capitani S; Neri LM
Oncotarget; 2014 Oct; 5(20):10034-47. PubMed ID: 25296981
[TBL] [Abstract][Full Text] [Related]
46. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
Ni H; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Hitoshi Y; Ansell SM; Treon SP; Thomas SK; Lee HC; Wang Z; Davis RE; Orlowski RZ
Clin Cancer Res; 2018 Dec; 24(24):6408-6420. PubMed ID: 30126942
[TBL] [Abstract][Full Text] [Related]
47. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
[TBL] [Abstract][Full Text] [Related]
48. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
50. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
51. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
52. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
[TBL] [Abstract][Full Text] [Related]
53. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
54. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
Sacco A; Roccaro A; Ghobrial IM
Oncotarget; 2010 Nov; 1(7):578-582. PubMed ID: 21317453
[TBL] [Abstract][Full Text] [Related]
55. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.
Jin YP; Valenzuela NM; Ziegler ME; Rozengurt E; Reed EF
Am J Transplant; 2014 Apr; 14(4):806-19. PubMed ID: 24580843
[TBL] [Abstract][Full Text] [Related]
56. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
57. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
58. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
[TBL] [Abstract][Full Text] [Related]
59. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
[TBL] [Abstract][Full Text] [Related]
60. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
